irinotecan has been researched along with alendronate in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Dobhal, S; Jaggi, M; Kumar, V; Negi, LM; Talegaonkar, S; Verma, AK; Verma, R | 1 |
| Cai, X; Chen, H; Cheng, Y; He, X; Huang, Q; Li, Y; Lin, K; Wang, Y; Xiao, J; Zhang, Q; Zou, Y | 1 |
1 review(s) available for irinotecan and alendronate
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for irinotecan and alendronate
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part I. Synthesis, characterization and in vitro investigation.
Topics: Alendronate; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Line, Tumor; Cell Survival; Drug Carriers; Flow Cytometry; HT29 Cells; Humans; Hyaluronan Receptors; Hyaluronic Acid; Inhibitory Concentration 50; Irinotecan; Lipids; Nanostructures | 2014 |
Multifunctional melanin-like nanoparticles for bone-targeted chemo-photothermal therapy of malignant bone tumors and osteolysis.
Topics: Alendronate; Animals; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Cells, Cultured; Combined Modality Therapy; Durapatite; Heterografts; Hyperthermia, Induced; Indoles; Infrared Rays; Irinotecan; Melanins; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Osteolysis; Phototherapy; Polymers; Tissue Distribution | 2018 |